ProQR Therapeutics N.V. (PRQR) is a Netherlands-based company that operates as a biopharmaceutical firm, focusing on the development and commercialization of treatments for rare, genetic diseases. The company takes a unique approach to tackling genetic disorders by correcting RNA mutations through a process called RNA repair. This process aims to correct the genetic fault causing the disease, with the hope of providing a one-time treatment.
Founded in 2012 by Daniel de Boer, a father inspired by his son's diagnosis of cystic fibrosis, ProQR Therapeutics has grown into a leading entity within the genetic therapeutics industry. As of now, it has several products in its pipeline addressing various disorders such as Leber’s congenital amaurosis 10 (LCA10), Usher syndrome, and dystrophic epidermolysis bullosa, among others.
The company's lead product candidate, sepofarsen (QR-110), is being developed for Leber's congenital amaurosis, a rare inherited retinal disease that affects infants and children, leading to vision loss. In Phase 1/2 and Phase 2/3 clinical trials, sepofarsen demonstrated substantial improvement in vision in treated patients, reflecting the potential of ProQR's RNA-targeting therapeutics.
Another key candidate in their pipeline is QR-421a for Usher syndrome and retinitis pigmentosa, diseases characterized by the progressive loss of both hearing and vision. This therapy is in the early stages of clinical development, permitting the testing of its safety and efficacy.
Expanding its focus, ProQR is developing Q-101, an RNA-based therapy targeting cystic fibrosis, the disease that initially inspired the company's foundation. This condition causes severe damage to the lungs and digestive system, affecting around 70,000 people globally.
ProQR Therapeutics N.V., listed on the NASDAQ (PRQR), continues to leverage cutting-edge RNA technology to create a transformative impact on patients' lives afflicted by severe genetic disorders. The passion and ambition behind the company have been recognized through partnerships with leading institutions and pharmaceutical companies. Determined to make a difference, ProQR carries its mission of breaking new grounds within genetic diseases by addressing the underlying cause with transformative RNA medicines.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $7.60, despite the stock recently trading near its 52-week low. The biopharmaceutical company exceeded quarterly expectations, reporting a loss of $0.09 per share against an estimated $0.13 loss and revenue of $10 million, significantly higher than the $4.56 million anticipated by analysts. Institutional investors have also been adjusting their positions in the company, with several increasing their holdings.
HC Wainwright has revised its FY2028 earnings per share estimate for ProQR Therapeutics (NASDAQ:PRQR) to a loss of $0.37, a reduction from its prior forecast of a $0.27 loss, while maintaining a "Buy" rating and an $8.00 price target. The biopharmaceutical company recently reported a narrower-than-expected quarterly loss of $0.09 per share and revenue of $10 million, significantly beating analyst estimates. Analyst sentiment generally remains positive with a "Moderate Buy" consensus, and company insiders have recently purchased a substantial amount of shares.
ProQR Therapeutics announced the first human validation of its RNA-editing platform for liver disease, showing dose-dependent target engagement for its AX-0810 candidate. The treatment, aimed at cholestatic liver diseases like pediatric biliary atresia, demonstrated no serious adverse events and increased plasma bile acids. ProQR expects data from its next-generation candidate, AX-0811, in early 2027, which is designed for greater potency and durability.
ProQR Therapeutics N.V. (PRQR) released a slide deck for a shareholder/analyst call held on September 30, 2026. The article highlights that the content was published in conjunction with this event and was prepared by Seeking Alpha's transcripts team.
HC Wainwright has lowered its price target for ProQR Therapeutics (NASDAQ:PRQR) to $8.00 while maintaining a "buy" rating, indicating a potential upside of 381.93%. Other analysts have also issued reports on the biopharmaceutical company, resulting in an average rating of "Moderate Buy" and an average price target of $7.60. The company recently reported better-than-expected earnings and saw significant insider buying.